Inotrem and Roche Diagnostics Sign a R&D Collaboration Agreement in the Field of Septic Shock to Develop a Companion Diagnostic Test
Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, today announced a R&D collaboration agreement with Roche Diagnostics to develop a companion diagnostic test using a soluble plasma circulating protein (sTREM-1) developed by Inotrem and the Roche proprietary Elecsys® platform. It is Roche Diagnostics’ first collaboration agreement with a start-up biotech company.
Under the terms of the agreement, Roche and Inotrem will work together to develop an in vitro robust prototype assay for quantitative measurement of soluble TREM-1 (sTREM-1) in plasma samples of septic shock patients. sTREM-1 is a marker of the activation of the TREM-1 immune amplification pathway and high sTREM-1 plasma concentrations have been shown to be associated to a negative outcome in septic shock patients. Measurement of sTREM-1 in blood could provide a valuable indicator for the diagnosis and outcome prediction of septic shock patients.
Inotrem is currently conducting a clinical Phase 2 trial in patients with septic shock to demonstrate the benefit of its lead compound, Motrem™ (LR12) in the treatment of septic shock. The collaboration with Roche Diagnostics may lead to a companion diagnostic supporting the development of Motrem™.
“One of the main issues with septic shock is the heterogeneity of this patient population. This collaboration proposes to develop a test to allow a certain stratification of sepsis patients to ideally identify patients who are more likely to respond to Motrem treatment,” said Jean-Jacques Garaud, CEO and co-founder of Inotrem. “It shows our shared willingness to accelerate the development of targeted therapeutic solutions for these patients.”
The physiopathology of septic shock is characterized by an intense and excessive systemic inflammatory reaction in response to a serious infection. Its consequences include the dysfunction of vital organs and major hemodynamic disorders that may prove fatal for patients. Activation of the TREM-1 pathway is recognized as a key factor contributing to septic shock.
“As a leader in in vitro diagnostics solutions, it is a great opportunity to participate to the opening of a new front in critical care medicine, particularly in an area known for its difficult and highly heterogeneous population in septic shock”, shared Jean-Claude Gottraux, Head of Roche Diagnostics, Centralized and Point of Care Solutions. “We are particularly pleased as this is the first time Roche Diagnostics is collaborating with a start-up biotech company.”
Anne REIN, +33 6 03 35 92 05
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
The Indian Detective, Starring Russell Peters, Premieres Tuesday, December 19, 2017 on Netflix Worldwide20.11.2017 19:00 | Tiedote
Full release here. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005203/en/ (Photo: Business Wire) Following today’s announcement by Netflix, THE INDIAN DETECTIVE , a four-part comedy-drama series starring international comedy sensation Russell Peters, award-winning actor Anupam Kher (The Big Sick, Silver Linings Playbook), the iconic William Shatner (Star Trek), Christina Cole (Suits, Casino Royale), Hamza Haq (mother!, Bon Cop, Bad Cop 2), Akshay Kumar (Star Wars Ep VIII), Meren Reddy (Madiba, Homeland) and Mishqah Parthiephal (Keeping Up with the Kandasamys, Snake Park), will premiere on December 19, 2017 on Netflix worldwide, following an initial run on CTV Canada in November.
Andersen Global Expands Presence in Italy with New Location in Venice-Mestre, on the Venetian Mainland20.11.2017 17:30 | Tiedote
Andersen Global is proud to announce a new presence in Venice-Mestre, on the Venetian mainland in Italy through the expansion of Italian member firm, Andersen Tax & Legal. In addition, the Milan office will relocate at the end of November. The new office in Mestre and new location in Milan have been established to better serve the growing client base in Italy. Andersen Tax & Legal now has six locations in Italy: Milan, Brescia, Rome, Venice, Mestre, and Monza. Andrea De Vecchi, Office Managing Partner of Andersen Tax & Legal in Italy, and Regional Managing Partner in Europe shared, “Our new location in Venice-Mestre and expanded presence in Milan allow us to better serve our clients and continue to build our capabilities within the region. Through this expansion, we are able to reach new markets and also improve the quality of life for our employees.” Venice-Mestre is a sign
NexPlayer HTML5 Player Fully Compatible with Conviva across All Browsers and Devices20.11.2017 17:00 | Tiedote
NexStreaming, the provider of NexPlayer SDK, the market leader player SDK for OTT apps, announced today that the NexPlayer HTML5 player is fully compatible with Conviva Video AI Platform. This pre-integrated solution brings great value to video services: from now on, they will be able to enable the highest quality HLS & DASH live streaming across all browsers and devices with NexPlayer, and ensure an outstanding user experience with accurate analytics about the quality of the video experience thanks to Conviva. In this technology integration, NexPlayer HTML5 is fully optimized with Conviva’s QoE analytics. NexPlayer sends information regarding the use of the HTML5 based OTT service, including when the user pauses the video or the video is buffering as well as information about the frame-rate. Conviva measures and analyzes this information so that video service providers and publishers
AGCO’s Innovation Rewarded with Prestigious Awards at Agritechnica 201720.11.2017 17:00 | Tiedote
AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and solutions, achieved remarkable success with 17 major awards at the prestigious Agritechnica 2017 event in Hannover, Germany. As a result of the votes cast by an independent expert committee, AGCO was once again one of the most successful manufacturers at Agritechnica 2017 by way of the number of innovation awards received. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005614/en/ The new Fendt Track Tractor 943 Vario MT won the treasured award "Machine of the Year 2018" in the Category XXL Tractors (Photo: Business Wire) “Winning these significant awards is a testament to our continued commitment to deliver high-tech solutions for farmers feeding the world,” said Martin Richenhagen
Leading Broker ActivTrades Wins Le Fonti Forex Broker of the Year Award for the Second Time20.11.2017 16:30 | Tiedote
ActivTrades, one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/ ActivTrades was awarded at the Le Fonti Awards (Photo: Business Wire) A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre. Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” a
European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients20.11.2017 16:30 | Tiedote
Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has granted approval to broaden the existing marketing authorisation for ZYTIGA® (abiraterone acetate) plus prednisone / prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. Abiraterone acetate plus prednisone / prednisolone can now be used for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).1 “Prostate cancer is the most common form of cancer in men throughout Europe and today’s decision helps to fill a critical medical need for these patients. We hope to significantly improve the lives of many men across Europe living with this disease and the approval of this treatment in an earlier stage of prostate cancer helps address this,”
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme